top of page
Executive Spotlights

Flare Therapeutics Names Dr. Douglas Manion as New CEO

Cambridge, MA, April 23 2024 (PRNewswire) -- Flare Therapeutics Inc. has undergone a notable leadership transition with the selection of Dr. Douglas Manion, M.D., FRCP (C), as its newly appointed Chief Executive Officer. This strategic move highlights the company's dedication to propelling precision medicine initiatives aimed at combatting cancer and related health challenges via pioneering methods focusing on transcription factors.

Read full article here.

Recent Posts

See All

R3 Vascular Raises $87M in Series B Financing

Mountain View, CA, May 20, 2024 (FinSMEs) -- R3 Vascular, a medical device firm headquartered in California, secured $87 million in Series B financing. The funding round, spearheaded by Deerfield Ma


Life Science Headlines
bottom of page